
Axonis Therapeutics Announces $115 Million Series A Financing
Axonis Therapeutics Announces $115 Million Series A Financing — Oversubscribed financing brings together leading syndicate of life sciences investors —

Axonis Therapeutics Announces $115 Million Series A Financing — Oversubscribed financing brings together leading syndicate of life sciences investors —

Businesswire reports emerging biotechnology company AXONIS Therapeutics, Inc. has secured an additional $5 million in funding and provided an update

The Massachusetts Life Sciences Center (MLSC) named Axonis, Inc. CEO Joanna Stanicka a 2020 winners of the Massachusetts Next Generation

AXONIS are delighted to be awarded the Astellas-sponsored “Golden Ticket Competition.” A Golden Ticket award offers entrepreneurial scientists or emerging biotechnology startups one-year

May 28: AXONIS Therapeutics, Inc. announces the close of the first tranche of a $4 million Seed Preferred financing.

The International Space Station (ISS) U.S. National Laboratory and Boeing [NYSE: BA] have partnered for the sixth consecutive year to

Congratulations to Axonis, the winner of our latest Innovation Prize in Boston for their work in neuro-restorative research in spinal
We use cookies to improve your experience on our site. By using our site, you consent to cookies.
Manage your cookie preferences below:
Essential cookies enable basic functions and are necessary for the proper function of the website.
Google reCAPTCHA helps protect websites from spam and abuse by verifying user interactions through challenges.
You can find more information in our Cookie Policy and .